CFTR channel pharmacology: Insight from a flock of clones. focus on "divergent CFTR orthologs respond differently to the channel inhibitors CFTR inh-172, glibenclamide, and GlyH-101"

American Journal of Physiology - Cell Physiology

Volumn 302, Issue 1, 2012, Pages

  Sheppard, David N ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLIBENCLAMIDE; GLYCINE DERIVATIVE; HYDRAZIDE DERIVATIVE; ION CHANNEL; TRANSMEMBRANE CONDUCTANCE REGULATOR;

ALLOSTERISM; ATTENUATION; CONCENTRATION RESPONSE; CYPRINODONTIFORMES; DIMERIZATION; DOGFISH; DOMESTIC PIG; DRUG BINDING SITE; DRUG POTENCY; DRUG SPECIFICITY; EDITORIAL; HUMAN; HYDROPHOBICITY; ION TRANSPORT; NONHUMAN; ORTHOLOGY; OSMOREGULATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN STRUCTURE; RECTUM GLAND; SALINITY;

ANIMALS; BENZOIC ACIDS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; FEMALE; GLYBURIDE; GLYCINE; HUMANS; HYDRAZINES; MALE; THIAZOLIDINES;

EID: 83455176280     PISSN: 03636143     EISSN: 15221563     Source Type: Journal    
DOI: 10.1152/ajpcell.00376.2011     Document Type: Editorial

References (11)

1. Cui G, Song B, Turki HW, McCarty NA. Differential contribution of TM6 and TM12 to the pore of CFTR identified by three sulphonylureabased blockers. Pflügers Arch. In press.
2. Kopeikin Z, Sohma Y, Li M, Hwang TC. On the mechanism of CFTR inhibition by a thiazolidinone derivative. J Gen Physiol 136: 659-671, 2010.
3. Li H, Sheppard DN. Therapeutic potential of cystic fibrosis transmembrane conductance regulator (CFTR) inhibitors in polycystic kidney disease. BioDrugs 23: 203-216, 2009.
4. Linsdell P. Location of a common inhibitor binding site in the cytoplasmic vestibule of the cystic fibrosis transmembrane conductance regulator chloride channel pore. J Biol Chem 280: 8945-8950, 2005.
5. Liu X, Luo M, Zhang L, Ding W, Yan Z, Engelhardt JF. Bioelectric properties of chloride channels in human, pig, ferret, and mouse airway epithelia. Am J Respir Cell Mol Biol 36: 313-323, 2007.
6. Moran O, Galietta LJ, Zegarra-Moran O. Binding site of activators of the cystic fibrosis transmembrane conductance regulator in the nucleotide binding domains. Cell Mol Life Sci 62: 446-460, 2005.
7. Price MP, Ishihara H, Sheppard DN, Welsh MJ. Function of Xenopus cystic fibrosis transmembrane conductance regulator (CFTR) Cl_ channels and use of human-Xenopus chimeras to investigate the pore properties of CFTR. J Biol Chem 271: 25184-25191, 1996.
8. Sheppard DN. CFTR channel pharmacology: novel pore blockers identified by high-throughput screening. J Gen Physiol 124: 109-113, 2004.
9. Stahl M, Stahl K, Brubacher MB, Forrest JN Jr. Divergent CFTR orthologs respond differently to the channel inhibitors CFTRinh-172, glibenclamide, and GlyH-101. Am J Physiol Cell Physiol (September 21, 2011). doi:10.1152/ajpcell.00225.2011.
10. Taddei A, Folli C, Zegarra-Moran O, Fanen P, Verkman AS, Galietta LJ. Altered channel gating mechanism for CFTR inhibition by a highaffinity thiazolidinone blocker. FEBS Lett 558: 52-56, 2004.
11. Verkman AS, Galietta LJ. Chloride channels as drug targets. Nat Rev Drug Discov 8: 153-171, 2009.